The NQO1/p53/SREBP1 axis promotes hepatocellular carcinoma progression and metastasis by regulating Snail stability

被引:0
作者
Xinyue Wang
Ying Liu
Anna Han
Chunxiao Tang
Ran Xu
Linyuan Feng
Yang Yang
Liyan Chen
Zhenhua Lin
机构
[1] Key Laboratory of Pathobiology (Yanbian University),Central Laboratory
[2] State Ethnic Affairs Commission,undefined
[3] The Affiliated Hospital of Yanbian University,undefined
来源
Oncogene | 2022年 / 41卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related mortality worldwide, and its abnormal metabolism affects the survival and prognosis of patients. Recent studies have found that NAD(P)H quinone oxidoreductase-1 (NQO1) played an important role in tumor metabolism and malignant progression. However, the molecular mechanisms by which NQO1 regulates lipid metabolism during HCC progression remain unclear. In this study, bioinformatics analysis and immunohistochemical results showed that NQO1 was highly expressed in HCC tissues and its high expression was closely related to the poor prognosis of HCC patients. Overexpression of NQO1 promoted the cell proliferation, epithelial-to-mesenchymal transition (EMT) process, and angiogenesis of HCC cells. Luciferase reporter assay further revealed that NQO1/p53 could induce the transcriptional activity of SREBP1, consequently regulating HCC progression through lipid anabolism. In addition, Snail protein was stabilized by NQO1/p53/SREBP1 axis and triggered the EMT process, and participated in the regulatory role of NQO1/p53/SREBP1 axis in HCC. Together, these data indicated that NQO1/SREBP1 axis promoted the progression and metastasis of HCC, and might be a potential therapeutic target for HCC.
引用
收藏
页码:5107 / 5120
页数:13
相关论文
共 249 条
[1]  
Singal AG(2020)Epidemiology and surveillance for hepatocellular carcinoma: New trends J Hepatol 72 250-61
[2]  
Lampertico P(2018)O-GlcNAcylation of RACK1 promotes hepatocellular carcinogenesis J Hepatol 68 1191-202
[3]  
Nahon P(2021)Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma Nat Rev Gastroenterol Hepatol 18 293-313
[4]  
Duan F(2021)Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma Front Immunol 12 783236-45
[5]  
Wu H(2017)Targeting metastasis-initiating cells through the fatty acid receptor CD36 Nature 541 41-66
[6]  
Jia D(2017)TIP30 regulates lipid metabolism in hepatocellular carcinoma by regulating SREBP1 through the Akt/mTOR signaling pathway Oncogenesis 6 748-5
[7]  
Wu W(2019)Metabolic rearrangements in primary liver cancers: cause and consequences Nat Rev Gastroenterol Hepatol 16 530-34
[8]  
Ren S(2020)The gluconeogenic enzyme PCK1 phosphorylates INSIG1/2 for lipogenesis Nature 580 1520-6
[9]  
Wang L(2019)A Regulatory Role of Apoptosis Antagonizing Transcription Factor in the Pathogenesis of Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma Hepatology 69 243-49
[10]  
Llovet JM(2015)The CREB coactivator CRTC2 controls hepatic lipid metabolism by regulating SREBP1 Nature 524 732-53